New stem cell therapy aims to free patients from lifelong blood transfusions
NCT ID NCT04390971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment called ET-01 in 3 people with transfusion-dependent beta-thalassemia, a blood disorder that requires regular blood transfusions. The treatment uses the patient's own stem cells, which are modified and then transplanted back. The goal was to see if it is safe and can reduce or eliminate the need for transfusions by helping the body produce healthy red blood cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION DEPENDENT BETA-THALASSAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, 563000, China
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.